International AIDS Vaccine Initiative & Merck & Co.

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative (IAVI) received an initial $3.2 million from CEPI to develop a single-dose Bundibugyo vaccine candidate using technology similar to Merck's Ervebo.

Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing rVSV Bundibugyo, a single-dose vaccine candidate seen as promising by the World Health Organization, though it is not yet ready for trials.

Merck & Co.: Merck & Co. developed Ervebo, the only licensed Ebola vaccine, which the World Health Organization reviewed but recommended against deploying outside research settings for the Bundibugyo strain due to limited evidence.

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.